Acetylcholine
As of the edition of 20 October 2026, Acetylcholine is a small molecule: marketed, first approved in 1982 (US); acts on CHRM3; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2006
- Kind
- Small molecule
- Brand name
- Miochol
- First approved
- 1 January 1982 (US)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Laboratoire Chauvin; 3 holders in all
- Registered trials
- 38, 9 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Blood and lymph; Urinary and reproductive; Hormones; Pregnancy and women's health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Acetylcholine.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 14 | 5 | 3 | 2 |
| Phase 1 | 17 | 6 | 6 | 4 |
| Phase 2 | 7 | 4 | 0 | 3 |
| All trials | 38 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Acquired holder | 2004 to now |
| Bausch Health | Acquired holder | 2011 to now |